Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mupirocin is a naturally occurring topical antibiotic derived from *Pseudomonas fluorescens*, primarily used to treat superficial skin infections such as impetigo, folliculitis, and secondary traumatic skin lesions caused by susceptible bacteria including *Staphylococcus aureus* (including MRSA) and *Streptococcus pyogenes*. It is also used intranasally for the eradication of nasal carriage of MRSA. Mupirocin acts by reversibly inhibiting bacterial isoleucyl-tRNA synthetase, leading to inhibition of protein synthesis and ultimately bacteriostasis or bactericidal effects at higher concentrations. It does not exhibit cross-resistance with other classes of antibiotics due to its unique mechanism. Mupirocin is available only in topical formulations because it undergoes rapid systemic metabolism. Common side effects include local irritation such as burning, stinging, or itching at the application site[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mupirocin.